This study was implemented to compare the value of PET, CT, and dual-modality PET/CT
imaging for assessing gastrointestinal stromal tumor (GIST) response to imatinib therapy …

Gastrointestinal stromal tumors (GISTs) are gaining the interest of researchers because of
impressive metabolic response to the targeted molecular therapeutic drug imatinib mesylate …

OBJECTIVE. We correlated changes in tumor density on CT with changes in glucose
metabolism, or the maximum standardized uptake value (SUVmax), on FDG PET and sought …

OBJECTIVE. We report results from a pilot study aimed at optimizing the use of CT
bidimensional measurements and 18F-FDG PET maximum standardized uptake values …

Purpose Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in
evaluating gastrointestinal stromal tumors (GISTs) treated with imatinib. This study evaluates …

Purpose Gastrointestinal stromal tumours (GIST) are mesenchymal neoplasms of the
gastrointestinal tract that are unresponsive to standard sarcoma chemotherapy. Imaging of …

Background The new anti-cancer drug imatinib mesylate inhibits the tyrosine kinase growth
factor receptor, c-KIT, and has shown spectacular activity in patients with gastrointestinal …

Imatinib mesylate (Glivec®, formerly STI571) is the first effective systemic treatment for
gastrointestinal stromal tumours (GISTs). Major changes in tumour volume, however, tend to …

Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose
Positron Emission Tomography in Patie Page 1 Early Prediction of Response to Sunitinib After …

The reliability of established anatomical imaging techniques, such as computed tomography
(CT) and magnetic resonance imaging (MRI), is compromised in following response to …